Literature DB >> 7844959

Use of subcutaneous vascular access ports in rhesus monkeys.

F H Wojnicki1, J D Bacher, J R Glowa.   

Abstract

To investigate new approaches for treatment of drug abuse, subcutaneous vascular ports were implanted in rhesus monkeys (Macaca mulatta) for use in drug self-administration studies. Internal or external jugular veins were cannulated, and the catheter was attached to a subcutaneous port that was positioned on the back between the shoulder blades. This port/catheter system allowed easy serial blood sampling and intravenous drug administration. Daily use of the ports in awake monkeys was simple, effective, and caused no apparent stress over a 2-h experimental session. At the time of submission, the mean functional lifetime of the port/catheter system in 20 monkeys implanted longer than 6 months was 243.61 days, with the upper range being 540 days. Several complications developed with this system, and solutions to these problems are described. With proper aseptic use, the subcutaneous vascular port system provided a safe and enduring method for daily access for intravenous sampling and/or drug delivery. The duration of the preparation is a considerable improvement compared with exteriorized catheterization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7844959

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  24 in total

1.  Impact of self-administered cocaine and cocaine cues on extracellular dopamine in mesolimbic and sensorimotor striatum in rhesus monkeys.

Authors:  C W Bradberry; R L Barrett-Larimore; P Jatlow; S R Rubino
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

2.  Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use.

Authors:  C W Bradberry
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

3.  Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation.

Authors:  Patricia V Turner; Cynthia Pekow; Mary Ann Vasbinder; Thea Brabb
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

Review 4.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

5.  Hypocretin/orexin antagonists decrease cocaine self-administration by female rhesus monkeys.

Authors:  Richard W Foltin; Suzette M Evans
Journal:  Drug Alcohol Depend       Date:  2018-05-25       Impact factor: 4.492

6.  Development of translational preclinical models in substance abuse: Effects of cocaine administration on cocaine choice in humans and non-human primates.

Authors:  Richard W Foltin; Margaret Haney; Eric Rubin; Stephanie C Reed; Nehal Vadhan; Rebecca Balter; Suzette M Evans
Journal:  Pharmacol Biochem Behav       Date:  2015-04-28       Impact factor: 3.533

7.  Refinement of vascular access port placement in nonhuman primates: complication rates and outcomes.

Authors:  Melanie L Graham; Lucas A Mutch; Eric F Rieke; Michele Dunning; Elizabeth K Zolondek; Aaron W Faig; Bernhard J Hering; Henk-Jan Schuurman
Journal:  Comp Med       Date:  2010-12       Impact factor: 0.982

8.  Self administration of cocaine in monkeys receiving LAAM acutely or chronically.

Authors:  Lisa R Gerak; Ruggero Galici; Charles P France
Journal:  Physiol Behav       Date:  2007-07-28

9.  Effects of menstrual cycle phase on cocaine self-administration in rhesus macaques.

Authors:  Ziva D Cooper; Richard W Foltin; Suzette M Evans
Journal:  Horm Behav       Date:  2012-10-23       Impact factor: 3.587

10.  Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

Authors:  Suzette M Evans; Richard W Foltin; Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Kim D Janda; Stephen M Kaminsky; Ronald G Crystal
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.